SCHEDULE: Hong Kong Pharma Digital Tech Sees 65% Stake Acquired

Liying Wang, through TUTU Business Services Limited, has acquired a 65% controlling stake in Hong Kong Pharma Digital Technology Holdings Limited, triggering a significant management overhaul.

Summary

• Liying Wang, through TUTU Business Services Limited, acquired 7,150,000 ordinary shares of Hong Kong Pharma Digital Technology Holdings Limited.
• This acquisition represents a 65% controlling stake in the company, based on 11,000,000 ordinary shares outstanding as of October 6, 2025.
• The aggregate purchase price for these shares was HK$53,820,000, equivalent to approximately US$6,900,000.
• The acquisition was funded by Liying Wang's personal funds.
• The transaction led to immediate and significant changes in the company's executive leadership and board, including the appointment of a new CEO, CFO, and Chief Strategy Officer, and the resignation of the previous CEO, CFO, COO, and an Executive Director.

Sentiment

Score: 7

Explanation: The acquisition of a controlling stake by a new investor and the subsequent comprehensive management restructuring indicate a significant strategic shift. While the immediate impact is uncertain, the new leadership and strong ownership position could lead to a revitalized strategic direction and potential for future growth in the pharmaceutical digital technology sector.

Positives

• A new controlling shareholder with a significant stake (65%) may bring fresh capital, strategic direction, and operational efficiencies.
• The appointment of new executive leadership, including a new CEO, CFO, and Chief Strategy Officer, could signal a renewed focus on growth and performance.
• The appointment of an independent director, Mr. Zhou Mike Yao, may enhance corporate governance.

Negatives

• The immediate and widespread changes in key management positions (CEO, CFO, COO, Executive Director, CSO) could lead to short-term operational disruption or uncertainty.
• The filing does not provide specific reasons for the previous management's resignations, which could be a point of concern.
• The shares acquired are restricted securities, limiting immediate liquidity for the purchaser.

Risks

• The Sale Shares are restricted securities as defined in Rule 144 under the Securities Act and are subject to resale restrictions.
• The company's business could be materially and adversely affected by ongoing, pending, or threatened legal proceedings or changes in applicable laws in the region or sector.
• The Purchaser is restricted from engaging in hedging transactions involving the Sale Shares unless in compliance with the Securities Act.
• The Purchaser is restricted from offering or selling the Sale Shares to any U.S. Person or in the United States during the applicable distribution compliance period, except pursuant to an effective registration statement or a valid exemption.

Future Outlook

The Reporting Persons may increase or decrease their position in the Company, and evaluate various strategic alternatives. These alternatives may include, but are not limited to, proposing or considering a merger, consolidation, reorganization, recapitalization, asset acquisition, asset sale, or other business combination involving the Company; a change in the present board of directors or management; a material change in the present capitalization or dividend policy; or a material change in the Company's business or corporate structure.

Management Comments

• The Reporting Persons purchased the Shares based on the Reporting Persons' belief that the Shares, when purchased, represented an attractive investment opportunity.

Industry Context

Hong Kong Pharma Digital Technology Holdings Limited operates in the pharmaceutical cross-border e-commerce and distribution sector. This acquisition and management change could signify a strategic pivot or an attempt to capitalize on evolving trends in digital health and international pharmaceutical supply chains, particularly within the Asian market. The new leadership may bring different expertise or a new vision to navigate this competitive and regulated industry.

Management Changes

Corporate Governance

Legal Proceedings

• No criminal or civil proceedings against the Reporting Persons in the last five years.
• The Group is not a party to any material proceedings, and no material proceedings are threatened or pending by or against the Group.
• No investigations, disciplinary proceedings, or other circumstances are reasonably likely to lead to any material claim or legal action against the Group.

Related Party Transactions

• The Share Purchase Agreement was executed between TUTU Business Services Limited (Purchaser) and five Sellers. Liying Wang is the sole shareholder and director of TUTU Business Services Limited and is also one of the Reporting Persons. The filing does not explicitly state if the sellers are related parties to the company or the new purchaser, but the transaction itself represents a significant change in ownership structure.

Stakeholder Impact

• Shareholders: Existing minority shareholders will now have a 65% controlling shareholder, potentially leading to changes in company strategy, dividend policy, and future valuation. The new management team could bring new opportunities or risks.
• Employees: Significant changes in top management (CEO, CFO, CSO) could create uncertainty but also new opportunities for employees under the new leadership.
• Customers/Suppliers: Changes in company strategy or operations under new management could impact existing relationships, potentially leading to new business approaches or partnerships.
• Creditors: Any material changes in capitalization or business structure, as contemplated by the new controlling shareholder, could affect the company's financial risk profile.

Next Steps

• The Purchaser will instruct the Escrow Agent to release Escrowed Documents upon full payment of the Completion Payment.
• Sellers will procure a book entry statement of account and a certified copy of the shareholders list for the Purchaser within three business days following Completion.
• Sellers will cooperate with the Purchaser for 14 months post-Completion to ensure timely filing of all reports required under the Exchange Act, including XBRL compliance.
• The Escrowed Balance will be released to the Sellers upon the Company's filing of its annual report on Form 20-F for the fiscal year ending March 31, 2026.

Key Dates

Recommendation

The filing details a significant change of control, with a new entity acquiring a 65% stake and immediately implementing a comprehensive overhaul of the company's executive leadership. This introduces substantial uncertainty regarding the company's future strategic direction, operational focus, and financial performance. While a new controlling shareholder and management team could be a catalyst for positive change, investors should await further clarity on the new leadership's plans and vision before making definitive investment decisions. A "hold" recommendation allows for observation of these developments.

Keywords

Hong Kong Pharma Digital Technology, Liying Wang, TUTU Business Services, Schedule 13D, beneficial ownership, change of control, pharmaceutical e-commerce, management change, CEO, CFO, independent director, share acquisition, corporate governance